featured
Apalutamide Plus Abiraterone Acetate and Prednisone in Metastatic Castration-Resistant Prostate Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Apalutamide Plus Abiraterone Acetate and Prednisone Versus Placebo Plus Abiraterone and Prednisone in Metastatic Castration-Resistant Prostate Cancer (ACIS): A Randomised, Placebo-Controlled, Double-Blind, Multinational, Phase 3 Study
Lancet Oncol 2021 Sep 30;[EPub Ahead of Print], F Saad, E Efstathiou, G Attard, TW Flaig, F Franke, OB Goodman, S Oudard, T Steuber, H Suzuki, D Wu, K Yeruva, P De Porre, S Brookman-May, S Li, J Li, S Thomas, KB Bevans, SD Mundle, SA McCarthy, DE RathkopfFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Advanced Prostate Cancer Center of Excellence
Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.